Free Trial
NASDAQ:AYTU

Aytu BioPharma (AYTU) Stock Price, News & Analysis

Aytu BioPharma logo
$1.50 +0.05 (+3.45%)
(As of 12/24/2024 05:19 PM ET)

About Aytu BioPharma Stock (NASDAQ:AYTU)

Key Stats

Today's Range
$1.45
$1.55
50-Day Range
$1.34
$2.33
52-Week Range
$1.30
$3.45
Volume
25,820 shs
Average Volume
23,903 shs
Market Capitalization
$9.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

Aytu BioPharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
19th Percentile Overall Score

AYTU MarketRank™: 

Aytu BioPharma scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Aytu BioPharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aytu BioPharma is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aytu BioPharma is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aytu BioPharma has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.00% of the float of Aytu BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Aytu BioPharma has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aytu BioPharma has recently decreased by 1.99%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aytu BioPharma does not currently pay a dividend.

  • Dividend Growth

    Aytu BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.00% of the float of Aytu BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Aytu BioPharma has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aytu BioPharma has recently decreased by 1.99%, indicating that investor sentiment is improving.
    • Insider Buying vs. Insider Selling

      In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 2.77% of the stock of Aytu BioPharma is held by insiders.

    • Percentage Held by Institutions

      Only 33.49% of the stock of Aytu BioPharma is held by institutions.

    • Read more about Aytu BioPharma's insider trading history.
    Receive AYTU Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

    AYTU Stock News Headlines

    Aytu BioPharma Proposes Settlement in Shareholder Lawsuit
    Why I'm telling friends to avoid gold stocks
    Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
    Aytu BioScience Announces Leadership Change and Financial Growth
    Aytu BioPharma Reports Q1 Fiscal 2025 Earnings
    Aytu BioPharma Names Ryan Selhorn as CFO
    See More Headlines

    AYTU Stock Analysis - Frequently Asked Questions

    Aytu BioPharma's stock was trading at $2.84 on January 1st, 2024. Since then, AYTU stock has decreased by 47.2% and is now trading at $1.50.
    View the best growth stocks for 2024 here
    .

    Aytu BioPharma, Inc. (NASDAQ:AYTU) posted its quarterly earnings results on Thursday, September, 26th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.37. The firm had revenue of $17.98 million for the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 21.89% and a negative net margin of 8.28%.

    Aytu BioPharma shares reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Aytu BioPharma's top institutional investors include Stonepine Capital Management LLC (8.15%). Insiders that own company stock include Joshua R Disbrow and Greg Pyszczymuka.
    View institutional ownership trends
    .

    Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
    Compare Top Brokerages Here.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), General Electric (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE).

    Company Calendar

    Last Earnings
    9/26/2024
    Today
    12/25/2024
    Fiscal Year End
    6/30/2025

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:AYTU
    Fax
    N/A
    Employees
    160
    Year Founded
    N/A

    Profitability

    Net Income
    $-15,840,000.00
    Pretax Margin
    -6.76%

    Debt

    Sales & Book Value

    Annual Sales
    $79.76 million
    Book Value
    $4.64 per share

    Miscellaneous

    Free Float
    5,979,000
    Market Cap
    $9.22 million
    Optionable
    Not Optionable
    Beta
    -1.40
    7 Stocks to Own Before the 2024 Election Cover

    Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

    Get This Free Report

    This page (NASDAQ:AYTU) was last updated on 12/25/2024 by MarketBeat.com Staff
    From Our Partners